NCT06674850Not yet recruiting
Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia
Assessment of the Prognostic Role of Systemic Inflammatory Index, Systemic Inflammation Response Index and C-Reactive Protein to Albumin Ratio in Acute Lymphoblastic Leukemia
Source: ClinicalTrials.gov · Last updated 5 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
the goal of this observational study is Assesment of systemic inflammatory index (SII) , system inflammation response index (SIRI) and CRP Albumin ratio(CAR) as biomarkers for ALL prognosis.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 36 (estimated)
- First submitted
- 27 Oct 2024
- Start date
- Nov 2024
- Primary completion date
- Nov 2025
- Lead sponsor
- Assiut University
- NCT number
- NCT06674850
What you commit to
- Study type: Observational
- Planned participants: 36
- From Nov 2024 to the primary completion date, Nov 2025
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of other hematological disorders( other than ALL)
- History of other malignancies, or relapsed ALL.
- 2- Patients under chemotherapy or radiotherapy. 3- Signs of inflammation 5- Evidence of autoimmune disease.
Who the study is looking for
- Newly diagnosed ALL patients that admitted to the South Egypt Cancer Institute and not received any treatment.
Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.